This patent teaches how to genetically delete the MHC antigens in order to have stem cells and progeny of the stem cells that are capable of acting as universal donor cells. Although this technology is at face value very interesting, the fact that other antigens besides MHC cause rejection of tissue dampens enthusiasm for this approach. Additionally, the ability of recipient immune system to cause immune activation through indirect antigen presentation also is a cause of concern for efficacy of this approach.
View this patent on the USPTO website.
You must be signed-in to add your comments.
Sign-in now or Join the StemCellPatents.com Community for free.